Emerging Tools for Alzheimer's Disease

Jun 2023| MDS089A| BCC Publishing
Sample Report

Report Highlights

The goal is to provide an analysis of the emerging tools for the early detection of Alzheimer’s disease (AD) and their growth potential and future opportunities in the market. Because currently available tools are invasive and very expensive, there is a significant unmet need for non-invasive, cost-effective and early-detection tools. The study’s main objective is to present a comprehensive analysis of the emerging tools, including those that are approved and those in development, and predict their impact on the market.

Report Includes

  • An overview of the global market for emerging tools for the early detection of Alzheimer’s disease
  • Estimation of the market size and analyses of global market trends, with data from 2020 to 2022, estimates for 2023 with projections of compound annual growth rates (CAGRs) through 2028
  • Highlights of the current and future market potential and quantification of market based on type and region
  • Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
  • Detailed analysis of the regulatory framework and policies and product pipeline of the industry
  • Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis

Report Scope

The report provides an overview of AD, and the current diagnostic methods. The report explains the need for emerging tools for the early detection of the disease. Tools that have been approved are discussed, as well as tools in the development phase. The report does not include therapeutics approved or in the pipeline for AD.

The report covers the global market for emerging tools with a look at the regional markets of North America, Europe and Emerging Markets.

The report provides a detailed analysis of the current and future global market for emerging tools. Industry growth drivers, restraints and opportunities are also discussed. The report also provides a look at the competitive landscape, profiles of companies developing tools for the early detection of AD, and the impact of COVID-19 on the market.

Frequently Asked Questions (FAQs)

The global market for emerging tools for Alzheimer’s disease was estimated to be $814.7 million in 2022, and the market is expected to increase to nearly $1.7 billion through 2028, growing at a compound annual growth rate (CAGR) of 13.6% during the forecast period.
The key factors contributing to the growth of the market include increasing prevalence of Alzheimer’s disease, high unmet need, need for identifying right patients for clinical trials, increasing investments and funding.
In this report, the market is segmented based on region.
North America holds the highest share in the market.
Key companies in the market include C2N Diagnostics, Fujirebio Diagnostics, QUEST Diagnostics, Roche and Quanterix.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $814.7 million
Market size forecast $1.7 billion
Growth rate CAGR of 13.6%
Units considered $ Millions
Segments covered region
Regions covered North America, Europe, and Emerging Markets
Key Market Drivers
  • Increasing Prevalence of Alzheimer’s Disease
  • High Unmet Need
  • Need to Identify the Right Patients for Clinical Trials
  • Increasing Investments and Funding
Companies studied
  • ALTPEP
  • ARACLON BIOTECH
  • C2N DIAGNOSTICS
  • COGNOPTIX
  • DIADEM SPA
  • F. Hoffmann-La Roche AG
  • FUJIREBIO DIAGNOSTICS
  • QUANTERIX CORP.
  • QUEST DIAGNOSTICS
  • SYSMEX CORP.

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Emerging Tools for Alzheimer's Disease51Free
Emerging Tools for Alzheimer's Disease

Single User License: $3500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS